QualityStocksNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Advances GelrinC(R) Manufacturing With New Solvent-Free Production Process
Regentis Biomaterials (NYSE American: RGNT) announced the development of a new proprietary solvent-free manufacturing process for GelrinC(R), its off-the-shelf hydrogel implant for treating focal articular knee cartilage injuries, that more than quadruples production yield per batch. The company said the new process is designed to improve production economics and gross margins ahead of GelrinC(R)’s planned European commercial launch later this year, while patent filings for the manufacturing innovation have already been granted in India, China and Israel, with U.S. approval pending. To view the full press release, visit https://ibn.fm/HYySr About Regentis Biomaterials Regentis Biomaterials Ltd is a regenerative medicine company…